Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
T7-010-02
- Development stage
- Phase 2
- Lead developer
- Brigham and Women's Hospital
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
T7-010-02 is an investigational humanized monoclonal antibody being developed by T7 Therapeutics for the treatment of autoimmune and inflammatory diseases, with an initial focus on psoriatic arthritis. The therapeutic targets T-cell immune response cDNA 7 (TIRC7), a key immune checkpoint membrane protein co-localized with the T-cell receptor that plays a critical role in T-cell activation and immune regulation. By targeting TIRC7, T7-010-02 aims to modulate T-cell activation, suppress T-cell proliferation, and decrease the secretion of pro-inflammatory cytokines. The drug is currently being evaluated in a Phase 1/2a clinical trial in the United Kingdom.
02
Targets
ATP6V0A3 (V-ATPase a3 subunit)
Beyond the preview
Go deeper on T7-010-02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on T7-010-02.